US-CONGRESS S1041: Affordable Prescriptions for Patients Act
S.1041, the Affordable Prescriptions for Patients Act, has advanced to the Senate Legislative Calendar. This bill aims to reduce drug prices by targeting anti-competitive practices in the pharmaceutical industry, including patent thickets, product hopping, and pay-for-delay settlements. It may impact branded drug makers' patent strategies and generic/ANDA manufacturers' market entry timelines.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 22, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline, but businesses should prepare for possible enactment within the current congressional session (2025-2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The bill has been placed on the Senate Legislative Calendar (Calendar No. 44), indicating it is ready for floor consideration. This increases the likelihood of passage and requires businesses to prepare for potential changes in patent and market exclusivity rules.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
Monitor legislative progress and assess potential impacts on patent portfolios, ANDA filing strategies, and settlement agreements. Engage with legal counsel to evaluate exposure to anti-competitive practice claims.
Deadline
No immediate deadline, but businesses should prepare for possible enactment within the current congressional session (2025-2026).
Source: https://www.congress.gov/bill/119th-congress/senate-bill/1041
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS BILLS-119hr2821eh: FDA Modernization Act 3.0
- US-CONGRESS BILLS-119hr9599ih: Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act; SECURE 340B Act
- Determination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- US-CONGRESS BILLS-119hr9774ih: To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
- US-CONGRESS BILLS-119hr9790ih: Modernizing Opioid Treatment Access Act 2.0 of 2026